The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Jul 18, 2026
Snapshot (as of Jul 18, 2026): Pfizer Inc. (PFE) pays a $1.72 annual dividend ($0.43 quarterly), yielding 6.87% at $25.05/share. Next ex-dividend date 2026-07-24. 15 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 6.87%
Annual Dividend: $1.72 per share
Payout Ratio: 130.5%
Ex-Dividend Date: 2026-07-24
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 55
Pfizer Inc. dividend investors are looking at one of the highest yields in the healthcare sector, currently sitting at 7.08%. The company, founded in 1849, develops and sells a broad portfolio of medicines and vaccines, including Eliquis for cardiovascular health, Paxlovid for COVID-19, and the Prevnar family of vaccines. PFE pays $1.72 per share annually in quarterly installments, with the next ex-dividend date on July 24, 2026. At a beta of 0.295, PFE stock moves far less than the broader market, which suits income-focused investors who prioritize price stability over capital gains.
Pfizer Inc. pays out 130.5% of earnings as dividends, a payout ratio classified as high (above 75%). That figure means PFE is currently paying more in dividends than it earns, which is only sustainable if earnings recover or the company draws on other resources. Pfizer Inc. dividend safety is directly tied to whether its diversified product base, spanning prescription drugs, vaccines, and biosimilars across multiple therapeutic areas, can generate sufficient earnings to close that gap. The payout ratio at 130.5% is the single most significant pressure point for the dividend right now.
Pfizer Inc. dividend history shows a CAGR of 5.6% per year from 2011 to 2025. Per-share payments grew from $0.80 to $1.72 over that period (2026 data is partial and excluded from this calculation). The smallest annual increase in the window was 2.4% in 2024, which shows that growth has slowed materially in recent years after a peak increase of 10.0% back in 2012.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +2.4% | $1.60 (2022) | $1.72 (2025) |
| 5-Year | +2.5% | $1.52 (2020) | $1.72 (2025) |
| 10-Year | +4.4% | $1.12 (2015) | $1.72 (2025) |
PFE stock is built for income-focused investors who want a high current yield from a large, diversified biopharmaceutical business. The 7.08% yield is classified as high (above 4%) and sits above the 5-year average of 6.75%, which reflects recent price weakness rather than a dividend increase. The trade-off is real: a payout ratio of 130.5% means the dividend is not covered by current earnings, and dividend growth has slowed to 2.4% annually as of 2024. What an investor gets is a large, immediate income stream from a company with 15 consecutive years of dividend increases. What they accept is meaningful uncertainty about how long that payout ratio remains manageable.
| Payment Date | Amount per Share |
|---|---|
| 2026-07-24 | $0.4300 |
| 2026-05-08 | $0.4300 |
| 2026-01-23 | $0.4300 |
| 2025-11-07 | $0.4300 |
| 2025-07-25 | $0.4300 |
| 2025-05-09 | $0.4300 |
| 2025-01-24 | $0.4300 |
| 2024-11-08 | $0.4200 |
| 2024-07-26 | $0.4200 |
| 2024-05-09 | $0.4200 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.2900 |
| 2025 | $1.7200 |
| 2024 | $1.6800 |
| 2023 | $1.6400 |
| 2022 | $1.6000 |
Project income from PFE with the PFE dividend calculator or track your full portfolio with the dividend tracker.